These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Dai C; Liang S; Sun B; Kang J Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722 [TBL] [Abstract][Full Text] [Related]
5. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas. Nf L; Ai M Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517 [TBL] [Abstract][Full Text] [Related]
7. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039 [TBL] [Abstract][Full Text] [Related]
9. How effective is temozolomide for treating pituitary tumours and when should it be used? Halevy C; Whitelaw BC Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528 [TBL] [Abstract][Full Text] [Related]
11. Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre. Rak B; Maksymowicz M; Grzywa TM; Sajjad E; Pękul M; Włodarski P; Zieliński G Endokrynol Pol; 2020; 71(2):116-125. PubMed ID: 32154573 [TBL] [Abstract][Full Text] [Related]
12. Pituitary tumour types in dogs and cats. Sanders K; Galac S; Meij BP Vet J; 2021 Apr; 270():105623. PubMed ID: 33641809 [TBL] [Abstract][Full Text] [Related]
13. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Hirohata T; Ishii Y; Matsuno A Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234 [TBL] [Abstract][Full Text] [Related]
15. Rab3B immunoexpression in human pituitary adenomas. Rotondo F; Scheithauer BW; Kovacs K; Bell DC Appl Immunohistochem Mol Morphol; 2009 May; 17(3):185-8. PubMed ID: 19384079 [TBL] [Abstract][Full Text] [Related]
16. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Raverot G; Jouanneau E; Trouillas J Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196 [TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794 [TBL] [Abstract][Full Text] [Related]